Alex Sparreboom
National Cancer Institute
Bethesda
Maryland 20892
USA
Name/email consistency: high
- Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Sparreboom, A., Scripture, C.D., Trieu, V., Williams, P.J., De, T., Yang, A., Beals, B., Figg, W.D., Hawkins, M., Desai, N. Clin. Cancer Res. (2005)
- Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Sparreboom, A., Marsh, S., Mathijssen, R.H., Verweij, J., McLeod, H.L. Invest. New. Drugs (2004)
- Herbal remedies in the United States: potential adverse interactions with anticancer agents. Sparreboom, A., Cox, M.C., Acharya, M.R., Figg, W.D. J. Clin. Oncol. (2004)
- Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Sparreboom, A., Gelderblom, H., Marsh, S., Ahluwalia, R., Obach, R., Principe, P., Twelves, C., Verweij, J., McLeod, H.L. Clin. Pharmacol. Ther. (2004)